This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Japan Agency for Medical Research and Development (AMED) | |
|---|---|
| Name | Japan Agency for Medical Research and Development |
| Formation | 2015 |
| Headquarters | Tokyo |
Japan Agency for Medical Research and Development (AMED)
The Japan Agency for Medical Research and Development (AMED) is a Japanese national funding and coordinating body created to integrate Ministry of Education, Culture, Sports, Science and Technology (Japan), Ministry of Health, Labour and Welfare (Japan), and Ministry of Economy, Trade and Industry (Japan) biomedical research functions, aiming to accelerate translational research, promote biomedical innovation, and coordinate responses to public health emergencies. AMED connects research institutes, universities, pharmaceutical companies, venture capital, and health technology bodies across Tokyo, Osaka, Kyoto, and other prefectures to facilitate collaboration among stakeholders such as University of Tokyo, Osaka University, Kyoto University, Riken, and National Cancer Center (Japan). Its formation shaped Japan’s landscape alongside entities like Japan Science and Technology Agency, Japan Agency for Marine-Earth Science and Technology, Japan International Cooperation Agency, and international partners including National Institutes of Health, European Research Council, and World Health Organization.
AMED was established in 2015 following policy processes involving the Cabinet of Japan, the Diet of Japan, and advisory committees including members from Japan Medical Association, Japan Pharmaceutical Manufacturers Association, and prominent academics such as figures from Keio University, Tohoku University, and Hokkaido University. The agency’s creation reflected reforms shaped by prior institutions like Ministry of Education, Culture, Sports, Science and Technology (Japan) research programs, the restructuring of Japan Science and Technology Agency (JST) activities, and lessons from outbreaks such as the 2011 Tōhoku earthquake and tsunami, the 2014 Ebola virus epidemic in West Africa, and concerns raised during the 2009 swine flu pandemic in Japan. Early strategic documents referenced frameworks from the Medical Research Council (UK), National Institutes of Health (United States), Institut Pasteur, and the European Commission to design funding streams and translational pathways. Legislative groundwork drew on precedents including laws administered by the Ministry of Health, Labour and Welfare (Japan) and consultations with the Organisation for Economic Co-operation and Development.
AMED’s governance structure includes a Board of Directors, a President, and advisory committees composed of clinicians, researchers, and industry leaders associated with institutions such as Tokyo Medical and Dental University, Juntendo University, Chiba University, Nagasaki University, Fukuoka University, and corporations like Takeda Pharmaceutical Company, Astellas Pharma, and Daiichi Sankyo. Oversight involves coordination with ministries including Ministry of Education, Culture, Sports, Science and Technology (Japan), Ministry of Health, Labour and Welfare (Japan), and Ministry of Economy, Trade and Industry (Japan), while programmatic review engages panels with representatives from Japan Society for the Promotion of Science, Pharmaceuticals and Medical Devices Agency (Japan), National Cancer Center (Japan), National Institute of Infectious Diseases (Japan), and international reviewers from Centers for Disease Control and Prevention (United States), European Medicines Agency, and Canadian Institutes of Health Research. Regional offices liaise with prefectural governments including Tokyo Metropolitan Government, Osaka Prefecture, and Kanagawa Prefecture to coordinate clinical trial networks and research hubs.
AMED’s mission emphasizes translational research from basic discoveries at institutions like Osaka University Graduate School of Medicine, Kyushu University, and Nagoya University into applied products developed by firms such as Sony Corporation health divisions and Panasonic Healthcare Company. Major funding programs support investigator-initiated grants, strategic funding for rare disease pipelines involving National Center for Child Health and Development (Japan), regenerative medicine initiatives linked to CiRA (Center for iPS Cell Research and Application), and precision oncology efforts with partners like Foundation Medicine. Programs mirror international schemes such as Horizon 2020, NIH R01, and Wellcome Trust awards, and include emergency response funds activated during events like the COVID-19 pandemic, involving coordination with Japan Self-Defense Forces medical units and public health authorities. AMED channels funds to clinical trials registered in platforms akin to ClinicalTrials.gov and supports commercialization pathways involving Japan External Trade Organization and venture networks.
AMED prioritizes areas including regenerative medicine linked to Shinya Yamanaka’s work at Kyoto University, cancer research with networks tied to National Cancer Center (Japan), infectious disease research involving National Institute of Infectious Diseases (Japan), rare diseases connected to patient groups such as Japanese Organization for Rare Disorders, and medical devices collaborating with corporations like Olympus Corporation and Hitachi. Initiatives cover genomics projects interfacing with Tohoku Medical Megabank Organization, neurodegenerative disease programs related to RIKEN Center for Brain Science, antimicrobial resistance research coordinated with the World Health Organization and G20 discussions, and aging-related studies aligned with demographic policy debates in the Cabinet Office (Japan). AMED funds multi-center clinical trials involving hospitals such as St. Luke's International Hospital and research centers including National Center for Global Health and Medicine.
AMED engages bilateral and multilateral collaborations with agencies like National Institutes of Health (United States), European Commission, Global Fund to Fight AIDS, Tuberculosis and Malaria, Bill & Melinda Gates Foundation, Wellcome Trust, and national agencies including UK Research and Innovation, German Research Foundation, French National Centre for Scientific Research, Chinese Academy of Sciences, Korea Institute of Science and Technology, and Australian National Health and Medical Research Council. Partnerships support capacity building in regions served by Japan International Cooperation Agency and joint research consortia with institutions including Harvard Medical School, University of Cambridge, Karolinska Institutet, Institut Pasteur, Max Planck Society, and Scripps Research.
AMED has enabled translational outputs such as regenerative cell therapy trials originating from CiRA (Center for iPS Cell Research and Application), oncology biomarker developments referenced by Japan Cancer Research Resources Bank, and rapid-response research during the COVID-19 pandemic including vaccine and therapeutic studies involving Eisai Co., Ltd. and diagnostic test development with Sysmex Corporation. External evaluations by panels including members from Organisation for Economic Co-operation and Development, Japan Science and Technology Agency, Ministry of Health, Labour and Welfare (Japan), and peer reviewers from National Institutes of Health and European Research Council have assessed AMED’s effectiveness in accelerating clinical translation, recommending continued emphasis on public–private partnership models used by Innovative Medicines Initiative and cross-border consortia. Ongoing metrics include publications in journals such as Nature Medicine, The Lancet, Science Translational Medicine, patent filings with the Japan Patent Office, and commercialization outcomes tracked by Japan External Trade Organization.
Category:Medical research in Japan